Fate Therapeutics Inc (NASDAQ:FATE)
| 96.29 BATS BZX Real-Time Price As of 3:48pm ET |  -0.35 / -0.36%Today’s Change | 16.75 Today|||52-Week Range 121.16 | +5.89% Year-to-Date |
Latest FATE News | Press Releases
| FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses Feb 25 / Zacks.com - Paid Partner Content | Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar? Feb 17 / Zacks.com - Paid Partner Content |
| Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript Feb 25 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 96.64 |
| Today’s open | 95.96 |
| Day’s range | 93.51 - 98.78 |
| Volume | 77,692 |
| Average volume (3 months) | 1,078,869 |
| Market cap | $8.4B |
Data as of 3:48pm ET, 03/02/2021
Growth & Valuation
| Earnings growth (last year) | -46.22% |
| Earnings growth (this year) | +10.04% |
| Earnings growth (next 5 years) | -11.43% |
| Revenue growth (last year) | +194.33% |
| P/E ratio | NM |
| Price/Sales | 238.32 |
| Price/Book | 20.51 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ARWRArrowhead Pharmaceut... | -3.03 | -3.62% |
| XLRNAcceleron Pharma Inc | -3.72 | -2.65% |
| CRSPCRISPR Therapeutics ... | +0.07 | +0.05% |
| NBIXNeurocrine Bioscienc... | -7.96 | -7.26% |
Data as of 3:49pm ET, 03/02/2021
Financials
| Next reporting date | May 12, 2021 |
| EPS forecast (this quarter) | -$0.43 |
| Annual revenue (last year) | $31.4M |
| Annual profit (last year) | -$173.4M |
| Net profit margin | -551.59% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
